January  2006, 6(1): 129-150. doi: 10.3934/dcdsb.2006.6.129

Drug resistance in cancer chemotherapy as an optimal control problem

1. 

Department of Mathematics and Statistics, Southern Illinois University at Edwardsville, Edwardsville, IL 62026-1653

2. 

Dept. of Electrical and Systems Engineering, Washington University, St. Louis, Missouri, 63130-4899

Received  November 2004 Revised  August 2005 Published  October 2005

We analyze non cell-cycle specific mathematical models for drug resistance in cancer chemotherapy. In each model developing drug resistance is inevitable and the issue is how to prolong its onset. Distinguishing between sensitive and resistant cells we consider a model which includes interactions of two killing agents which generate separate resistant populations. We formulate an associated optimal control problem for chemotherapy and analyze the qualitative structure of corresponding optimal controls.
Citation: Urszula Ledzewicz, Heinz Schättler. Drug resistance in cancer chemotherapy as an optimal control problem. Discrete & Continuous Dynamical Systems - B, 2006, 6 (1) : 129-150. doi: 10.3934/dcdsb.2006.6.129
[1]

Urszula Ledzewicz, Shuo Wang, Heinz Schättler, Nicolas André, Marie Amélie Heng, Eddy Pasquier. On drug resistance and metronomic chemotherapy: A mathematical modeling and optimal control approach. Mathematical Biosciences & Engineering, 2017, 14 (1) : 217-235. doi: 10.3934/mbe.2017014

[2]

Urszula Ledzewicz, Heinz Schättler, Mostafa Reisi Gahrooi, Siamak Mahmoudian Dehkordi. On the MTD paradigm and optimal control for multi-drug cancer chemotherapy. Mathematical Biosciences & Engineering, 2013, 10 (3) : 803-819. doi: 10.3934/mbe.2013.10.803

[3]

Cristian Tomasetti, Doron Levy. An elementary approach to modeling drug resistance in cancer. Mathematical Biosciences & Engineering, 2010, 7 (4) : 905-918. doi: 10.3934/mbe.2010.7.905

[4]

Urszula Ledzewicz, Heinz Schättler. The Influence of PK/PD on the Structure of Optimal Controls in Cancer Chemotherapy Models. Mathematical Biosciences & Engineering, 2005, 2 (3) : 561-578. doi: 10.3934/mbe.2005.2.561

[5]

Shuo Wang, Heinz Schättler. Optimal control of a mathematical model for cancer chemotherapy under tumor heterogeneity. Mathematical Biosciences & Engineering, 2016, 13 (6) : 1223-1240. doi: 10.3934/mbe.2016040

[6]

Arturo Alvarez-Arenas, Konstantin E. Starkov, Gabriel F. Calvo, Juan Belmonte-Beitia. Ultimate dynamics and optimal control of a multi-compartment model of tumor resistance to chemotherapy. Discrete & Continuous Dynamical Systems - B, 2019, 24 (5) : 2017-2038. doi: 10.3934/dcdsb.2019082

[7]

Ami B. Shah, Katarzyna A. Rejniak, Jana L. Gevertz. Limiting the development of anti-cancer drug resistance in a spatial model of micrometastases. Mathematical Biosciences & Engineering, 2016, 13 (6) : 1185-1206. doi: 10.3934/mbe.2016038

[8]

Shuo Wang, Heinz Schättler. Optimal control for cancer chemotherapy under tumor heterogeneity with Michealis-Menten pharmacodynamics. Discrete & Continuous Dynamical Systems - B, 2019, 24 (5) : 2383-2405. doi: 10.3934/dcdsb.2019100

[9]

Urszula Ledzewicz, Heinz Schättler, Shuo Wang. On the role of tumor heterogeneity for optimal cancer chemotherapy. Networks & Heterogeneous Media, 2019, 14 (1) : 131-147. doi: 10.3934/nhm.2019007

[10]

Wei Feng, Shuhua Hu, Xin Lu. Optimal controls for a 3-compartment model for cancer chemotherapy with quadratic objective. Conference Publications, 2003, 2003 (Special) : 544-553. doi: 10.3934/proc.2003.2003.544

[11]

Craig Collins, K. Renee Fister, Bethany Key, Mary Williams. Blasting neuroblastoma using optimal control of chemotherapy. Mathematical Biosciences & Engineering, 2009, 6 (3) : 451-467. doi: 10.3934/mbe.2009.6.451

[12]

Avner Friedman, Najat Ziyadi, Khalid Boushaba. A model of drug resistance with infection by health care workers. Mathematical Biosciences & Engineering, 2010, 7 (4) : 779-792. doi: 10.3934/mbe.2010.7.779

[13]

Zhenzhen Chen, Sze-Bi Hsu, Ya-Tang Yang. The continuous morbidostat: A chemostat with controlled drug application to select for drug resistance mutants. Communications on Pure & Applied Analysis, 2020, 19 (1) : 203-220. doi: 10.3934/cpaa.2020011

[14]

Piotr Bajger, Mariusz Bodzioch, Urszula Foryś. Singularity of controls in a simple model of acquired chemotherapy resistance. Discrete & Continuous Dynamical Systems - B, 2019, 24 (5) : 2039-2052. doi: 10.3934/dcdsb.2019083

[15]

Luis A. Fernández, Cecilia Pola. Catalog of the optimal controls in cancer chemotherapy for the Gompertz model depending on PK/PD and the integral constraint. Discrete & Continuous Dynamical Systems - B, 2014, 19 (6) : 1563-1588. doi: 10.3934/dcdsb.2014.19.1563

[16]

Joseph Malinzi, Rachid Ouifki, Amina Eladdadi, Delfim F. M. Torres, K. A. Jane White. Enhancement of chemotherapy using oncolytic virotherapy: Mathematical and optimal control analysis. Mathematical Biosciences & Engineering, 2018, 15 (6) : 1435-1463. doi: 10.3934/mbe.2018066

[17]

Antonio Fernández, Pedro L. García. Regular discretizations in optimal control theory. Journal of Geometric Mechanics, 2013, 5 (4) : 415-432. doi: 10.3934/jgm.2013.5.415

[18]

K. Renee Fister, Jennifer Hughes Donnelly. Immunotherapy: An Optimal Control Theory Approach. Mathematical Biosciences & Engineering, 2005, 2 (3) : 499-510. doi: 10.3934/mbe.2005.2.499

[19]

Nicolas Bacaër, Cheikh Sokhna. A reaction-diffusion system modeling the spread of resistance to an antimalarial drug. Mathematical Biosciences & Engineering, 2005, 2 (2) : 227-238. doi: 10.3934/mbe.2005.2.227

[20]

Divya Thakur, Belinda Marchand. Hybrid optimal control for HIV multi-drug therapies: A finite set control transcription approach. Mathematical Biosciences & Engineering, 2012, 9 (4) : 899-914. doi: 10.3934/mbe.2012.9.899

2018 Impact Factor: 1.008

Metrics

  • PDF downloads (23)
  • HTML views (0)
  • Cited by (0)

Other articles
by authors

[Back to Top]